You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Colorcon
Medtronic
Mallinckrodt
Harvard Business School

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,320,740


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,320,740 protect, and when does it expire?

Patent 9,320,740 protects ZERBAXA and is included in one NDA.

This patent has twenty-one patent family members in fifteen countries.

Summary for Patent: 9,320,740
Title:Ceftolozane-tazobactam pharmaceutical compositions
Abstract: Pharmaceutical compositions are provided in unit dosage forms comprising ceftolozane and tazobactam in separate unit dosage form containers, ceftolozane prepared in the absence of tazobactam, tazobactam prepared in the absence of ceftolozane, and/or compositions where ceftolozane and tazobactam are first combined within a unit dosage form container.
Inventor(s): Terracciano; Joseph (Concord, MA), Damour; Nicole Miller (Belmont, MA), Jiang; Chun (Hillsborough, CA), Fogliato; Giovanni (Barzana, IT), Donadelli; Giuseppe Alessandro (Casalpusterlengo, IT), Resemini; Dario (Milan, IT)
Assignee: MERCK SHARP & DOHME CORP. (Rahway, NJ)
Application Number:14/214,221
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 9,320,740

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;INTRAVENOUS 206829-001 Dec 19, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,320,740

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014227660   Start Trial
Brazil 112015023523   Start Trial
Canada 2906151   Start Trial
Chile 2015002755   Start Trial
China 105392485   Start Trial
China 110279698   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Moodys
Harvard Business School
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.